Request to Appoint Tustee or Examiner in Biovest International, Inc. Case Denied
4/16/2013 8:58:43 AM
More...
|
Biovest International, Inc. Files for Bankruptcy
3/8/2013 8:20:58 AM
More...
|
Accentia Biopharmaceuticals (ABPI), Biovest International, Inc. Shrink Losses, Default on Debt
12/27/2012 8:16:32 AM
More...
|
Biovest International, Inc. Names Lymphoma Key Opinion Leader From MD Anderson Cancer Center to Scientific Advisory Board
9/11/2012 10:13:57 AM
More...
|
Biovest International, Inc. Conducts End of Phase III Review With FDA of BiovaxID™ as Consolidation Therapy in Non-Hodgkin's Lymphoma
8/14/2012 9:03:40 AM
More...
|
Biovest International, Inc. Advances Process Seeking European Marketing Approval for BiovaxID™ Personalized Lymphoma Vaccine
7/30/2012 10:02:38 AM
More...
|
Biovest International, Inc. Release: National Cancer Institute Study Demonstrates Significant Overall Survival and Time-to-Next-Treatment Benefits for BiovaxID® Cancer Vaccine Following Rituximab-Chemotherapy in Mantle Cell Lymphoma Study
6/7/2012 10:05:43 AM
More...
|
Biovest International, Inc. Announces BiovaxID® American Society of Clinical Oncology Abstract Available On-line; National Cancer Institute to Present Cancer Vaccine Data from Mantle Cell Lymphoma Study
5/18/2012 10:23:22 AM
More...
|
Biovest International, Inc. Retains Ferghana Partners to Evaluate Strategic Transactions
5/16/2012 10:16:21 AM
More...
|
Biovest International, Inc. to Seek Marketing Approval in the EU for BiovaxID® Personalized Lymphoma Cancer Vaccine
5/14/2012 9:05:03 AM
More...
|
|